13^th World Congress on Breast Cancer May 02-03, 2023 London, UK

Biography:

Mufeed J. Ewadh has his expertise in many fields of biochemistry research in his institute dealing with health problem, herbal extraction, alternative medicine .He participated in many international and local conferences and workshops which deal with improvement of biochemical research to increase people awareness about its role .He participated in post doctorate course in Marburg University (Germany) on 2005 ,and he participated in electrophoresis  workshop in japan for two weeks as well as in biochemical workshop  in Leipzig (Germany) / 2016.His postgraduate  supervision deals with many graduate students (M.Sc. and Ph.D.)  Which focus on publishing more than 160 papers in different local and international journals. His interest in publishing research paper made his institute to nominate him as the best professor for two years (2003),(2009) .He is chief in editor of most famous journal in Iraq (Medical  Journal of Babylon ) and he got many rewards during his scientific life.

Abstract:

The study aims to evaluate the diagnostic and prognostic value of kinesin-4A,β Tubulin and Exosomes as non-invasive biomarkers in Iraqi women with breast cancer first diagnosed and after mastectomy. Seventy Iraqi women with breast cancer diagnosed for the first time participated in the study, also seventy healthy women (control group) who did not have breast cancer. The study was approved by the local ethics committee. All persons participated in this study was agreed to participate and signed an informed consent. The period of this study extended from February 2021 to October 2022. This work was done in the Department of Biochemistry, College of Medicine, University of Babylon, The Oncology Center at Marjan Hospital and Surgical ward at Hilla Teaching Hospital in Hilla City, Iraq. All cases of breast cancer were diagnosed by Mammography, Various circulating biomarkers and tumor markers were investigated including hematological, and hepatic as well as oxidative stress markers, Serum Kinesin-4A (KIF4A), serum β Tubulin (TUBB) and plasma Exosomes (EVs).

Results at first time diagnosis show that (KIF4A) found to be increased in women with breast cancer (P < 0.01). (β TUBB) levels were very high in breast cancer women  (221.3 ± 17.2) compared to controls (33.4± 3.1; P < 0.001) while the levels of (EVs) was extremely high in breast cancer women compared to control group (P < 0.001). Two weeks after the mastectomy, the results of Kinesin-4A , β Tubulin and Exosomes were dropped dramatically near to normal levels. Results suggest that different types of breast cancer can altered several aspects of host immunity causing increased production of specific immune product. And these products can use as diagnostic and prognostic markers to reduce invasive procedures such as surgeries or radiation exposure.

Biography:

Dr. Anupalli Roja Rani has completed Bachelor's and Master's degree from Osmania University and Ph.D. in Life Science (Plant science Biotechnology) from Hyderabad Central University, Hyderabad under the guidance of Prof. G. Padmaja. She was selected for Raman Fellowship for Post Doctoral Research in United States of America for the year 2012-2013. Her areas of research interest include plant tissue culture, plant transformation, molecular biology, qualitative and quantitative assessment of biochemical compounds extracted from medicinal plant and to test for their medicinal properties against cancer and diabetes. She has organized several National conferences and workshops. She has completed UGC MJRP project, while CEPEPA, DST PURSE and DST-SERB funded projects are in progress. Currently, eight students are working for their Ph.D. degree under her supervision. She has 17 publications to her credit in International journals. She has visited Singapore and US.

Abstract:

Among several, breast cancer has emerged as the most common female cancer in developing countries. It is the most common cause of cancer related deaths worldwide among women.It is a molecularly and clinically heterogeneous disease. Moreover, it is a hormone – dependent tumor in which estrogens can regulate the growth of breast cells by binding with estrogen receptors (ERs) moreover, the use of natural products in cancer therapeutics are due to their properties of bio compatibility and less toxicity. Plants are the vast reservoirs for various bioactive compounds. Coleus barbatus (Lamiaceae) contains anticancer property against several cancer cell lines.

In the present study, an attempt is being made to enrich the knowledge of anticancer activity of pure compounds extracted from Coleus barbatus (Andrew). on human breast cancer cell lines MCF-7. Here in, we are assessing the antiproliferative activity of Coleus barbatus (Andrew) plant extracts against MCF 7 and also evaluating their toxicity in normal human mammary cell line such as HMEC. The active fraction of plant extract was further purified with the help of Flash chromatography, MPLC and preparative HPLC. The structure of pure compound will be elucidated by using modern spectroscopic method like NMR, ESI-MS methods. Later, the growth inhibition morphological assessment of cancer cells and cell cycle analysis of purified compound assessed using FACS. Growth and progression of signaling molecules HER2, GRP78 studied by secretion assay using ELISA and expression analysis by flow cytometry.

Cytoxoxic effect against MCF-7 with IC50 values were derived from doseresponse curves, using six concentrations of twofold serially diluted samples, by SOFTMax Pro software (Molecular device) and respectively Ellipticine and 0.5% DMSO were used as positive and negative control.

The present study shows the significance of various bio-active compounds extracted from Coleus barbatus (Andrew) root material. It acts as an anti-proliferative and shows cytotoxic effect on human breast cancer cell lines MCF7.The plant extracts play an important role pharmacologically. The whole plant has been used in traditional medicine for decades and the studies done have authentcated the practice. Earlier as describe the plant have been used in the ayurveda and homeopathy medicine. However more clinical and pathological studies must be conducted to investigate the unexploited potential of the plant. These studies are very useful for drug designing in future.

Biography:

Asifa Khan has her expertise in finding the natural compounds and their role in targeting cancer metabolism. She worked on the natural compounds and their effect on upstream and downstream metabolic pathways. She has experience in in silico studies as well. Through in silico studies she finds novel phytocopounds that could be the direct inhibitor of upregulated key glycolytic enzymes. She has the strong academic background as she secured gold medal in securing highest marks in her master’s (This is a certificate of excellence, most prestigious medal awarded to the only one student for securing highest marks in their relevant subject in the university). She also qualified NET (Life science) from Council of Scientific & Industrial Research (CSIR), securing 48th and 40th all over India rank, in 2017 and 2019 respectively. The National Eligibility Test (NET), is the examination for determining the eligibility for the post of assistant professor and in Indian universities. She has experience in research and in teaching graduate students. She is self-motivated, enthusiastic and eager to learn more.

Abstract:

Reprogrammed glucose metabolism is considered as the hallmark of the cancer with immense therapeutic relevance. Witahferin A (WA), a withanolide isolated from Withania somnifera has been shown to exhibit anticancer activity. But the role of WA in cancer metabolism still remain elusive. In line with this, we assessed the effect of WA on breast cancer metabolism and its underlying regulatory pathway. Herein, we showed that WA decreases the glucose uptake, lactate production and ATP generation in different breast cancer cell lines via suppression of key glycolytic enzymes i.e. GLUT1, HK2 and PKM2. We identified, WA induced suppression of glycolytic enzymes was through c-myc signaling - one of the major regulator of glycolysis.

Moreover, WA treatment significantly resulted in reduced cell viability, biomass and colony forming ability of breast cancer cells. Silencing of c-myc resulted in reduced glucose uptake, lactate production and ATP generation validating that regulation of Warburg effect is mediated through c-myc. Highlighting the importance of c-myc in glycolysis. To further validate our in vitro findings we used METABRIC dataset of ~2000 breast tumors and employed Pathifier algorithm to determine the pathway deregulation of glycolysis in each patient and normal sample Notably, highest deregulation of glycolysis was observed in breast tumor compared to normal tissues and found to be associated with poor prognosis. Taken together, our results highlight the anti- carcinogenic effect of Withaferin A in modulating breast cancer metabolism and the clinical significance of glycolysis in general.

Biography:

Sexual and Reproductive health expert and advocate with over 13 years’ experience in women’s rights and health. As a nurse health care manager, sociologist, trainer, mentor, and service provider she has ensured effective implementation of Integrated Sexual Reproductive Health and Rights in 23 counties in Kenya focusing on women as the central point of care. Currently as a program Associate at KMET she coordinates implementation of Reproductive, Maternal Neonatal and Adolescent Health interventions in 23 counties in Kenya through county, and community partnerships. Her passion has been having adolescent girls and women of reproductive age being integral and central to access friendly services using various innovations.

Abstract:

Breast cancer is among the most common cancers in Kenya with approximately 6,000 new cases and 2,500 deaths per year. Most of which present at advanced stages. Early detection combined with effective treatment can achieve survival probabilities of 90% or higher. The Kenyan Ministry of Health (MOH) is committed to reducing cancer mortality, as evidenced by policies such as the National Cancer Control Strategy (2017–2022). Although there are many Kenyan organizations devoted to this task, effective coordination is lacking resulting in inefficient and overlapping expenditure of resources. At community level, misconceptions and stigma surrounding cancer etiology, prevention, screening, and treatment have emerged increasing late detection and delays in early treatment. KMET in collaboration with Busia County Government, Department of Health and Stanbic Bank Foundation conducted a cancer prevention project dabbed Test & Treat with the aim of reducing the overall incidences, early diagnosis and treatment of breast cancer with HPV vaccination drive in 5 Sub Counties. The approach was through outreach base, incorporating cancer awareness creation sessions by use of Community Health Volunteers (CHVs) to increase self-examination, screening, and treatment at the community level.

Throughout the period of June- August 2022, a total of 917 women were reached with cancer awareness messages especially breast cancer, 453 women examined and 20 referred for further examinations and treatment in government facilities. Engage community leaders to identify and break key drivers of stigma during community awareness; develop culturally appropriate messages to address knowledge gaps on breast cancer; work with MOH for a coordinated referral systems from the community to facility level and advocate for a National Health Insurance Fund that supports the most vulnerable women access breast cancer treatment. Taking services to communities especially through outreaches ensures access to the most at need and reduces late diagnosis and treatment of breast cancer.

Biography:

Dr. El Hadji Seydou Mbaye was born in 1978 in Kaolack a region of Senegal. During 2008-2013, he earned his PhD in Biology and Human Pathologies with the collaboration of the International Agency for Research on Cancer / World Health Organization, (IARC/WHO), Lyon (France); He obtained a Master’s of Life and Health, Specialty Biology of microorganisms, Virology; a Master’s of Life and Health, option Immuno-physiopathology; a License of Biochemistry in Louis Pasteur University of Strasbourg (France); and a General Degree in Sciences and Technologies in University of METZ (France). He was certified Grade 10/10 by the Federation International of Gynecology Obstetric (FIGO), the Accreditation Council of Oncology in Europe (ACOE), and the Institute Catalan of Oncology (ICO). These credits were recognized as Physician’s Recognition Award (AMA PRA Category 1) by the American Medical Association. He was awarded as International Outstanding Scientist Awards 2020, Awarded as the Best Researcher Award 2021, by VDGOOD. He was certified, by the United Nations, by IARC/WHO. He has published 1 Book with a style of philosophical story. Author of the World Program against Cancer in Low and Middle Incomes Countries, he is lead author of more than 90 peer-reviewed research articles published in reputed journals. Dr. Mbaye is Editor-in-Chief of 4 journals, Editorial Board Member of 157 International Journals, and then he has Edited/Reviewed 270 peer-reviewed articles. He is member of Allied Academies, member of the World Society for Virology (WSV), member of World’s Leading Virologists Group: Facing to Covid-19, member of U.S. National Academies of Sciences, Engineering, and Medicine (NASEM): Societal Experts Action Network (SEAN), and also, member of BCNet International Working Group, IARC/WHO. Dr. MBAYE has formed for free, more than 250 Healthcare Professionals for the techniques of cervical cancer screening in Senegal. He has screened for free more than 2000 women for cervical cancer in Senegal.

Abstract:

Worldwide, one in eight deaths is due to cancer. Projections based on the GLOBOCAN 2012 estimates predict a substantive increase new cancer cases per year by 2035 in developing countries if preventive measures are not widely applied. According to the World Health Organization (WHO), millions of lives could be saved each year if countries made use of existing knowledge and the best cost-effective methods to prevent and treat cancer. Therefore, the aim of this study is to estimate a provisional budget against cancer in low and middle incomes countries, according the GNI-PPP, the cancer incidence and the number of population.

Economically country classification are determining with the Gross national income (GNI), per capita, Purchasing power parity (PPP), according the administrations of the International Monetary Fund (IMF); the World Bank (WB) and the Central Intelligence Agency (CIA). Cancer incidence data presented are based on the most recent data available at IARC. However, population compares estimates from the US Bureau of the Census. The provisional budget is establishing among the guidelines developed by WHO for regional and national cancer control programs according to national economic development.

A compilation of 91 articles representing 91 Programs against cancer in low and middle incomes countries are determining.

Provisional budget against cancer is estimated to 51,477,422.00 (thousands of U.S $) for a population of 3,682,702.05 (thousands peoples), in 91 low and middle incomes countries worldwide, according the GNI-PPP, the cancer incidence and the number of population.

Biography:

Ana Faustino is Professor at Department of Zootechnics of University of Évora and Researcher at CITAB/UTAD. She holds a Master in Veterinary Medicine and a European PhD in Veterinary Sciences. Animal models of cancer, tumoral angiogenesis and imaging are her main areas of interest. She has collaborating in several Financed Research projects. The results of her works were published in more than 250 publications in several formats. She received several prizes of scientific merit, and highlights and press honors. She has experience in supervising graduate and post-graduate students. She participated in several courses, workshops, international and national meetings. She is editorial member of several scientific journals and reviewer of more than 300 manuscripts. She is Guest Editor of two special issues in Veterinary Animals and in Life.

Abstract:

Breast cancer is one of the most frequent cancers among women worldwide. According to the World Health Organization, in the year 2020, breast cancer was diagnosed in approximately 2.3 million women, and victimized 685.00 women. The increasing number of breast cancer cases leads to the need to search for a more effective diagnostic and therapeutic approaches for breast cancer care. Animal models have been used since early times to understand several diseases. In vivo studies are essential to improve and discover new strategies to prevent and treat cancer more effectively, improving patients’ lifespan and quality of life. This presentation intends to describe the importance of animal models for breast cancer research, focusing on rodent models.

Biography:

Lotte Mulder earned her Master’s of Education from the Harvard Graduate School of Education in 2013, where she focused on Leadership and Group Development. She’s currently working toward a PhD in Organizational Leadership. At ASCP, Lotte designs and facilitates the ASCP Leadership Institute, an online leadership certificate program. She has also built ASCP’s first patient ambassador program, called Patient Champions, which leverages patient stories as they relate to the value of the lab.

Abstract:

Health literacy is associated with improved health outcomes. Primary care providers usually provide the majority of care to patients and are also usually the first point of contact for patients within a health system. A cancer diagnosis relies on pathology and laboratory medicine for the diagnosis and management of the disease. However, pathology reports are often encoded in jargon that patients cannot understand and patients do not always have direct access to their reports, limiting the patient's ability to make educated decisions. A new vision of health literacy in relation to pathology information is needed. What can we do so that all this scientific knowledge, which is currently unattainable due to the type of language being used, can be shared and used as a tool to inform people who are affected by cancer so they can make informed decisions about their own lives?

This session explains how oncologists, patient advocates, and primary health care doctors can utilize pathology results to increase their patients’ understanding of their diagnosis and lab test results, thereby increasing patients’ health literacy. This session will focus on equipping participants with a toolkit of pathology resources and strategies to effectively explain their pathology report, diagnosis, lab test results, and follow-up diagnostic care. These strategies are discussed within the context of both high and low-middle income country realities. Working towards this objective provides opportunities to strengthen healthcare systems and empower patients, and conduct research to determine the impact of different approaches. It’s imperative to work with all stakeholders across healthcare to advocate for a fundamental shift in the way we deliver knowledge that is built around the needs of people and their communities, in particular the knowledge and understanding of patients’ diagnoses.

The goal is to raise awareness about the relevance of the pathology results for the patient’s understanding of their treatment and prognosis, and how patients can use the pathology results as a decision-making tool.